6 Ways to Personalize Your Patient’s Asthma Treatment Plan
Asthma management is increasingly becoming more personalized. Here are 6 ways you can help personalize treatment for your patients with asthma that is severe or difficult to control.
In infancy, you can see feeding problems, and as the child progresses to adulthood, you will see them complain about vomiting, abdominal pain, difficulty swallowing, food impaction, and all of this may cause them to avoid eating certain foods, eat very slowly, or avoid social situations where food is involved.
In two replicate phase 3 trials involving patients with COPD who were receiving inhaled maintenance therapy, add-on tozorakimab resulted in a lower rate of moderate or severe exacerbations than placebo.
Frank C. Sciurba, Henrik Watz, Arnaud Bourdin, Wim Janssens, Fernando J. Martinez, Jinping Zheng, Maarten van den Berge, Matteo Bonini, MeiLan K. Han, Dave Singh, Gerard J. Criner, Christopher E. Brightling, Alberto Papi, Surya P. Bhatt, Martin Jenkins, Marta Mikosz, Piotr Chołbiński, Monika Ziemiecka, Magnus Löfdahl, Deepa Arya, Madhavi Yadavalli, Bryan H. Brodek, Malin Fagerås, Samuel Bardsley, Neil Martin, Rajesh Patel, Ioannis Psallidas, the OBERON and TITANIA Trial Investigators*
An interim analysis of a phase 3 randomized trial involving adults with IgA nephropathy showed that ravulizumab, a terminal complement inhibitor, led to a significantly greater reduction in proteinuria than placebo.
Jonathan Barratt, Youssef M.K. Farag, Kara Rice, Tobin J. Cammett, Lesley A. Inker, Hernán Trimarchi, Annette Bruchfeld, Hiddo J.L. Heerspink, Adrian Liew, Kevin Carroll, Hong Zhang, Sayna Norouzi, Shuang Hou, Sehoon Park, Miguel Ángel Pérez Valdivia, Jai Radhakrishnan, Yusuke Suzuki, Bonnie Schneider, John Marsala, Cynthia Carrillo-Infante, Stephen L. Lake, Ajay K. Singh, Stephen Nolan, Richard A. Lafayette, the I CAN Trial Group*
Among participants with IgA nephropathy, povetacicept, a dual inhibitor of B-cell activating factor and a proliferation-inducing ligand, led to a significantly greater reduction in proteinuria than placebo.
Jonathan Barratt, Hong Zhang, Seung Hyeok Han, Yuzuke Suzuki, James Tumlin, Bobby Chacko, Irene L. Noronha, Arvind Madan, Raphaël Duivenvoorden, Jamil R. Azzi, Carla Nester, Cassie Dong, Neil Ahluwalia, Jiahua Li, Carmen Bozic, Ogo Egbuna, Muh Geot Wong, Richard Lafayette, the RAINIER AIS-D08 Trial Group*
RMEI LIGHTNING TALKS
View Details
4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far
RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.
Allergy & Immunology
2021
View Details
Effectiveness of 5-year IBD Provider Online Educational Intervention Program
There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.
Latest Allergy & Immunology Articles
